| |
| |
|
| Insider
Information: |
Mammen Mathai |
| Relationship: |
EVP, Pharm, R&D |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
835,695 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$13,934,481 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
835,695 |
|
|
| Total
Value |
$13,934,481 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Innoviva Inc |
INVA |
SVP, Research & Early ... |
2014-08-20 |
334,040 |
|
0 |
Premium* |
|
|
Theravance Biopharma, Inc. |
TBPH |
SVP, Research & Develo... |
2016-03-15 |
288,111 |
|
0 |
Premium* |
|
|
10x Genomics, Inc. |
TXG |
|
2023-06-14 |
171,610 |
2021-06-11 |
0 |
Premium* |
|
|
Johnson & Johnson |
JNJ |
EVP, Pharm, R&D |
2022-02-15 |
41,934 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TXG |
10x Genomics, Inc. |
|
• • – |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,865 |
171,610 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
|
• • – |
2023-05-11 |
4 |
S |
$52.82 |
$1,743,086 |
D/D |
(33,000) |
169,745 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
|
• • – |
2023-05-11 |
4 |
OE |
$1.16 |
$232,000 |
D/D |
200,000 |
202,745 |
0 |
- |
|
| TXG |
10x Genomics, Inc. |
Director |
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,120 |
2,745 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-15 |
4 |
D |
$165.89 |
$558,386 |
D/D |
(3,366) |
41,934 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,740 |
45,300 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-14 |
4 |
D |
$168.85 |
$394,265 |
D/D |
(2,335) |
37,560 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&D |
• • – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,418 |
39,895 |
0 |
- |
|
| JNJ |
Johnson & Johnson |
EVP, Pharm, R&DOfficer |
• – – |
2022-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
32,477 |
|
% |
|
| TXG |
10x Genomics, Inc. |
Director |
– • – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
625 |
625 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
288,111 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2016-02-20 |
4 |
D |
$15.65 |
$310,559 |
D/D |
(19,844) |
198,111 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-11-20 |
4 |
D |
$17.17 |
$16,037 |
D/D |
(934) |
217,955 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-08-20 |
4 |
D |
$12.98 |
$12,123 |
D/D |
(934) |
218,889 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-06-02 |
4 |
D |
$13.83 |
$101,789 |
D/D |
(7,360) |
219,823 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-05-20 |
4 |
D |
$14.24 |
$9,584 |
D/D |
(673) |
227,183 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-02-20 |
4 |
D |
$19.52 |
$13,156 |
D/D |
(674) |
227,856 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Development |
• – – |
2015-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
130,000 |
228,530 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Early Clin Dev |
• – – |
2014-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(658) |
80,492 |
0 |
- |
|
| TBPH |
Theravance Biopharma, Inc... |
SVP, Research & Early Clin Dev |
• – – |
2014-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
81,150 |
|
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-08-20 |
4 |
D |
$22.76 |
$74,220 |
D/D |
(3,261) |
334,040 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
28,365 |
337,301 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
71,000 |
308,936 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-05-09 |
4 |
D |
$26.86 |
$613,294 |
D/D |
(22,833) |
239,136 |
0 |
- |
|
| INVA |
Innoviva Inc |
SVP, Research & Early Clin Dev |
• – – |
2014-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
261,969 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
